Stockwinners Market Radar for July 01, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:00 EDT Iterum Therapeutics PLC trading resumes

18:31 EDT Iterum says FDA identifies deficiencies as part of NDA review - Iterum Therapeutics announced that the company received a letter from the U.S. Food and Drug Administration stating that, as part of their ongoing review of the company's New Drug Application for sulopenem etzadroxil/probenecid, the agency has identified deficiencies that preclude the continuation of the discussion of labeling and post marketing requirements/commitments at this time. No details with respect to deficiencies were disclosed by the FDA in this notification and the letter further states that the notification does not reflect a final decision on the information under review. In a letter to the company dated January 21, 2021, the FDA had assigned a Prescription Drug User Fee Act goal date of July 25, 2021 for completion of its review of the NDA. The company intends to work with the FDA to understand the nature of the deficiencies and resolve them as quickly as possible. "While we are disappointed by this news, we continue to believe in the potential of sulopenem to help address the growing challenge of antibiotic resistance," said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. "Our goal now is to work with the FDA to identify and resolve the issues as expeditiously as possible in order to continue advancing this much needed antibiotic."

18:25 EDT Iterum Therapeutics PLC trading halted, news pending

18:18 EDT Virgin Galactic up over 2% at $44.18 after announcing first crewed spaceflight

18:08 EDT CytoDyn submits dose justification report to FDA over BLA for HIV - CytoDyn announced it has submitted a dose justification report to the U.S. Food and Drug Administration, which will be followed by an official submission to CytoDyn's IND. This is an integral step in the resubmission process for the Biologics License Application for HIV patients with multiple resistance to current standard of care. The dose justification report is a key component for the BLA and includes receptor occupancy analysis, among other factors, to determine the optimal marketed dose for leronlimab. Following FDA feedback on this critical step, CytoDyn will begin submission of BLA modules by specified timelines in accordance with FDA guidance and approval. Chris Recknor, M.D., CytoDyn's Chief Operating Officer and Head of Clinical Development, commented, "Our team has done a great job and remains focused on the goal of a BLA for HIV. We have a great molecule with many opportunities being evaluated in parallel to the BLA, including COVID, NASH and Oncology. We are on track for the top line report for the COVID-19 long-haulers symptoms/biomarker trial and will soon start two COVID-19 trials in Brazil. Our Phase 2 NASH trial has enrolled the 60th patient on schedule. We are working on our CCR5 solid tumor cancers basket trial and our triple-negative breast cancer dose escalation portion is completed with the main trial beginning in July. We are very excited about all we have ahead of us this year."

17:54 EDT Copart CEO sells 300K shares of common stock - In a regulatory filing, Copart disclosed that its CEO Jayson Adair sold 300K shares of common stock in a total transaction size of $40M.

17:17 EDT Cerence to replace Adtalem Global Education in S&P 400 at open on 7/7

17:14 EDT Raytheon Technologies awarded $2B Air Force contract - Raytheon has been awarded an approximately $2B cost-plus-fixed-fee with performance incentives contract for the engineering and manufacturing development, or EMD, phase of the Long Range Standoff, or LRSO, Weapon System. During the EMD phase, manufacturing processes will continue to mature and the manufacturing environment will be demonstrated and transitioned to a pilot line readiness state. The objective at the end of EMD is to demonstrate full production readiness. Work will be performed in Tucson, Arizona, and is expected to be completed February 2027. This contract is the result of a sole-source acquisition. FY21 research, development, test and evaluation funds are being obligated at the time of award. Air Force Nuclear Weapons Center is the contracting activity.

17:05 EDT LabCorp launches companion diagnostic for Amgen's lung cancer therapy - The company states: "Labcorp (LH) announced the availability of therascreen KRAS PCR Mutation Analysis, a companion diagnostic to identify patients with non-small cell lung cancer who are eligible for treatment with LUMAKRAS, a new treatment option developed by Amgen (AMGN). The therapy and this indicated use of the test as a companion diagnostic received approval from the FDA in late May 2021. The therascreen KRAS PCR Mutation Analysis is now available for ordering from Labcorp to determine if patients carry a specific mutation in the KRAS gene."

17:04 EDT Outset Medical CFO Rebecca Chambers steps down, Nabeel Ahmed named Interim CFO - Outset Medical CFO Rebecca Chambers will step down from her position to pursue other opportunities, effective July 16. Nabeel Ahmed, current VP, Finance, has been named Interim CFO effective upon Chambers' departure. Nabeel joined Outset in May 2020 as the company's VP, Controller. Prior to joining the company, Nabeel served as VP, Finance at 8x8, and as VP, Finance at Vocera Communications.

16:44 EDT NBA's Trail Blazers announces crypto platform StormX as jersey patch partner - The National Basketball Association's Portland Trail Blazers and cryptocurrency company StormX announced a significant multi-year jersey patch partnership beginning in the 2021-22 season to include placement of the StormX logo on the Trail Blazers game and practice jerseys. StormX, the Exclusive Blockchain Partner of the Portland Trail Blazers, is a Crypto Cashback provider and Chrome extension aiming to make earning crypto easy and accessible for anyone. "We are extremely excited to have our team wear such a groundbreaking, revolutionary company on the front of our jerseys," said Chris McGowan, President & CEO, Portland Trail Blazers and Rose Quarter. "StormX is a fresh, energetic company with Pacific Northwest roots that can educate and motivate Rip City around cryptocurrency and earning Crypto Cashback. I look forward to taking these next steps together as partners."

16:40 EDT Midwest Holding enters into reinsurance relationship with ARIC - Midwest Holding "announced that its subsidiary American Life & Security Corp. has entered into a reinsurance agreement with American Republic Insurance Company, or ARIC, a subsidiary of American Enterprise Group, Inc. Under the terms of the agreement, ARIC will assume an initial 20% quota share of certain Multi-Year Guaranteed Annuity and Fixed-Income Annuity policies issued by ALSC, effective January 1, 2021, up to $100M of premium. The agreement is renewable on an annual basis, subject to potential adjustment of the quota share, up to $100 million of premium per year."

16:35 EDT International Game to power sports betting at Coushatta Casino Resort, La. - International Game will power sports betting at Coushatta Casino Resort in Kinder, La.. As part of this agreement, IGT will deliver its PlaySports turnkey solution, including its trading advisory services.

16:32 EDT Danaos acquires remaining interest in Gemini Shipholdings - Danaos announced that it has exercised its option to acquire the remaining equity interests in its joint venture Gemini Shipholdings. The purchase price for the 51% of Gemini not already owned by the company is $86.7M in cash, while the net cash outflow for the company will be approximately $72.3M, which is the purchase price net of $14.4M of the Gemini cash balance on June 30. Gemini owns a fleet of five containerships, with an aggregate capacity of 32,531 TEU, each of which is employed on a time charter. Contract coverage for the Gemini vessels stands at 100% for the next 12 months while the weighted average contract duration of the Gemini fleet is 3.8 years, weighted by contracted revenues. Upon completion of the acquisition, the company will own 100% of Gemini and consolidate Gemini within its financial results. The consolidation of Gemini will increase the company's contracted revenue by approximately $160M and the Company's contracted EBITDA by approximately $117M in total. For the next 12 months, all of Gemini's vessels are employed on time charters and expected to contribute contracted EBITDA of $31M through June 30, 2022. Gemini's total debt and net debt, which will be assumed and consolidated by the company, was $45M and $30.6M, respectively, as of June 30.

16:18 EDT Krystal Biotech gives update on trial evaluating topical KB105 for ichthyosis - Krystal Biotech announced updated results from the Phase 1/2 clinical trial evaluating topical administration of KB105 in patients with autosomal recessive congenital ichthyosis ARCI associated with mutations in the TGM1 gene. These data show that repeat doses of KB105 continue to be well tolerated with no adverse events and with no evidence of immune response, systemically or at the sites of application. Phenotypic improvement, based on the IGA scale, was observed at each KB105 dosing site at varying time points throughout the 30-day dosing period, with the maximum effect observed in the treatment areas that received the highest KB105 dose. These results build on previous data showing a dramatic increase in KB105-mediated TGM-1 expression and activity in 3 patients, which correlated with an improvement on the IGA scale after KB105 topical treatment, with or without pretreatment of the area through micro-needling. No drug-related adverse effects were reported. "The totality of the data from our Phase 1/2 trial is encouraging, showing that topical application of KB105 to exfoliated skin results in detectable and correctly localized and functionally active TGM-1 enzyme," said Suma Krishnan, Chief Operating Officer of Krystal Biotech. "With this data in hand, we look forward to having continued discussions with patients and physicians to determine the optimal dosing regimen and endpoints to take forward into the next Phase 2 cohort, which we expect will include pediatric patients, in 2022."

16:16 EDT UGI Corporation names Jean Felix Tematio Dontsop CAO - UGI Corporation has named Jean Felix Tematio Dontsop as Vice President, Chief Accounting Officer, and Controller, effective July 19. Tematio Dontsop most recently served as Vice President of Internal Audit for West Pharmaceuticals in Exton, PA.

16:12 EDT Bank OZK boosts dividend to 28.5c per share - Bank OZK announced its Board of Directors has approved a regular quarterly cash dividend of 28c per common share payable July 19 to shareholders of record as of July 12. The dividend of 28.5c per common share represents an increase of 5v per common share, or 1.79%, over the dividend paid in the previous quarter. Bank OZK has increased its quarterly cash dividend in each of the last forty-four quarters.

16:09 EDT Oil-Dri Corporation of America to increase product prices up to 7% - Oil-Dri Corporation of America announced that it will increase prices for its agricultural, bleaching clay and fluid purification products. The price increases, effective August 1, will range up to 7% depending on the product.

16:06 EDT VBI Vaccines reports new CPT code issued for 3-Antigen Hep-B vaccine - VBI Vaccines reported that the American Medical Association Current Procedural Terminology Panel has established a unique CPT code for a 3-antigen Hepatitis B vaccine. If approved, VBI's 3-antigen HBV vaccine candidate will be reported using the new code, differentiating it from other single-antigen HBV vaccines. VBI's 3-antigen HBV vaccine candidate is currently under regulatory review for marketing approval in the U.S. and Europe. The FDA has set the PDUFA target action date of November 30, 2021.

16:06 EDT Merck to withdraw U.S. accelerated approval indication for Keytruda - Merck announced that the company plans to voluntarily withdraw the U.S. accelerated approval indication for KEYTRUDA for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 as determined by a U.S. Food and Drug Administration-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, human epidermal growth factor receptor 2/neu-targeted therapy. The decision was made in consultation with the FDA following the April 29 Oncologic Drugs Advisory Committee evaluation of this third-line gastric cancer indication for KEYTRUDA as a monotherapy because it failed to meet its post-marketing requirement of demonstrating an overall survival benefit in a Phase 3 study. As agreed with the FDA, Merck will initiate the withdrawal in six months. Patients being treated with KEYTRUDA for metastatic gastric cancer in the third- or further-line setting should discuss their care with their health care provider. This decision does not affect other indications for KEYTRUDA. "While there remains an unmet need for heavily pre-treated patients with advanced gastric cancer, we recognize that the treatment landscape has evolved and we respect the FDA's efforts to continually evaluate accelerated approvals," said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. "Our research with KEYTRUDA has contributed to recent advances in the treatment of gastric cancer, and we are continuing to advance studies to help more patients with this disease."

16:04 EDT Cidara Therapeutics announces James Levine resigns as CFO - Cidara Therapeutics announced that James Levine has resigned from his position as chief financial officer CFO, effective July 9, to pursue other opportunities. Mr. Levine will continue to serve as a consultant to the Company for at least six months and will provide transitional support to a successor CFO.

15:44 EDT Honda reports June U.S. sales up 33.4% to 153,122 units - Honda reports June U.S. sales rose 33.4% compared to the prior year to 153,122 units, including Honda division having "set a new June record" on sales of 137,238 units and Acura division sales rising 31.6% to 15,884 units. Honda reports Q2 sales grew 65.7% from the prior year to 486,419 units. Dave Gardner, executive vice president of National Operations at American Honda, said, "While we face more parts supply challenges ahead that will certainly impact our sales, I am humbled by the spirit and commitment of Honda associates across sales, production, R&D and purchasing who continue their efforts to serve our customers." Reference Link

15:03 EDT FCA US reports Q2 U.S. sales up 32% to 485,312 units - FCA US, a subsidiary of Stellantis, reported a 32% increase in second-quarter sales over the same time period a year earlier to 485,312 units. Retail sales rose 27% for the quarter. Fleet accounted for 12% of total sales. "The recovering U.S. economy and continued strong demand for our products drove unprecedented results. We continue to work closely with our suppliers to mitigate the manufacturing impacts caused by the various supply chain issues facing our industry," U.S. Head of Sales Jeff Kommor said. Stellantis will share its electrification strategy on Thursday, July 8, during its EV Day 2021 hosted by Stellantis CEO Carlos Tavares, the company noted.

14:09 EDT Regeneron says researchers find GPR75 mutations that protect against obesity - Regeneron Pharmaceuticals (REGN) announced that scientists from the Regeneron Genetics Center have discovered rare genetic mutations in the GPR75 gene associated with protection against obesity. "As reported in Science, almost 650,000 people were sequenced to find rare individuals with this genetic 'superpower,' providing new insights into the genetic basis of obesity. Potential therapeutics mimicking these genetic superpowers are being developed at Regeneron, utilizing its VelocImmune technologies and novel technologies from collaborators such as Alnylam Pharmaceuticals," the company stated. Regeneron scientists are pursuing multiple therapeutic approaches to target GPR75, including through antibodies, small molecules and gene silencing, the company noted. "The discovery of GPR75 is already enabling Regeneron and our collaborators to identify potential ways to safely replicate the effect of this mutation through novel therapeutic approaches. This is the latest in a long line of protective human genetics discoveries that have fueled new therapeutics programs at Regeneron. The pace is only quickening, as we uncover more and more about the human genome and work to rapidly translate those discoveries to the development of new medicines," added Aris Baras, M.D., Senior Vice President at Regeneron and Head of the Regeneron Genetics Center.

13:48 EDT Cameco trading resumes

13:35 EDT Volkswagen reports Q2 U.S. sales up 72% to 120,520 vehicles - Volkswagen of America reports Q2 2021 sales up 72% to 120,520, calling it the company's "best quarterly sales total since 1973." VW also called its May sales of over 44,000 its "best single month since 1973." Duncan Movassaghi, EVP and chief sales and marketing officer, Volkswagen of America, said: "Our growth has been led by our SUVs and their significant gains across some of the most competitive segments in the industry. The additions of the Taos and ID.4 enable us to sustain our recent gains and make us even more competitive as an SUV brand." Reference Link

13:27 EDT Custodian Ventures criticizes My Size for not producing requested documents - Custodian Ventures, a stockholder of My Size with an ownership interest of approximately 9.99% of the Company's outstanding shares, issued an open letter to fellow MYSZ stockholders. The letter read in part, "Custodian Ventures nominated four director candidates for election to MYSZ's Board of Directors at the 2021 Annual Meeting of Stockholders because it is our belief that with a change of tone at the top the Company's best days are still ahead of it...Instead of entering into a productive dialogue with us concerning our nominees' qualifications or the Company's future, this Board responded to our nomination by brazenly issuing nearly 20% of the Company's then outstanding shares to the Company's founder, who has known ties to certain nefarious elements wanted for securities fraud, in return for a waiver of the mere right held by this individual to repurchase certain intellectual property assets and receive royalty payments. We believe these rights, let alone the waiver thereof, are of little to no value given, among other things, the Company's apparent failure to seek an independent valuation of the underlying assets and the high likelihood that no royalty payments have ever been paid in connection therewith. As a result, on June 1, 2021, Custodian Ventures made a demand under Delaware law to inspect certain books and records of the Company to determine, among other things, whether there was any breach of fiduciary duties by members of the Board in approving this extremely dilutive transaction after we nominated our slate. To date, the Company has not produced any documents substantiating the legitimacy of this transaction nor has it made any attempt to otherwise defend substantively the Board's apparent entrenchment maneuver. Instead, the Company, through its counsel, has erected roadblocks to our legitimate information requests by requiring us to agree to what we believe are non-commercial terms and conditions which, among other things, seek to stifle our ability to communicate to stockholders our conclusions from our review of the documents produced. To be clear, any such conclusions drawn by Custodian Ventures will not contain any sensitive or otherwise proprietary Company information that stockholders should not be entitled to learn given the extremely value-destructive and suspicious nature of this transaction. Nonetheless, we have given the Company a deadline of July 6, 2021 to confirm that it will produce all of the documents requested in our Demand and until July 8, 2021 to substantially complete such production. In the event the Company does not comply in full with its obligations under Delaware law to produce the requested materials, we have reserved and are otherwise prepared to exercise our rights as stockholders of a Delaware corporation by filing suit in the Delaware Court of Chancery to compel the requested inspection. We call on the Board to refrain from taking any further actions which appear calculated to frustrate the exercise of stockholder democracy and shield the Board and management from accountability and to instead immediately announce the date of the 2021 Annual Meeting. The Company has held its last two annual meeting in early August. If it intended to be consistent with recent years, the Company should have set a record date and filed preliminary proxy materials by now. Any transparent attempts by the Board to avoid accountability by "running down the clock" will be summarily met by swift and decisive action by Custodian Ventures for the benefit of all of the Company's stockholders to compel the Board to hold the 2021 Annual Meeting in the statutorily-enumerated timeframe. Finally, given the ample $5.75 million in cash the Company reported on its books at the close of the first quarter of 2021, we urge the Board to reconsider authorizing any additional dilutive share issuances in a vain attempt to drown out the voice of its stockholders."

12:58 EDT Sony says 'Ghost of Tsushima Director's Cut' coming to PS5, PS4 in August - Sony subsidiary Sucker Punch Production announced that, on August 20, it will be releasing "Ghost of Tsushima Director's Cut," an enhanced version of 2020 PlayStation 4 video game "Ghost of Tsushima," on both PlayStation 5 and PS4 consoles. "This new edition comes packed not only with the original game and every piece of additional content we've sold to date, but a brand-new adventure for Jin alongside a bunch of new features that we're excited to reveal," said Andrew Goldfarb, communications manager at Sucker Punch. The PS5 version of the game will now offer lip sync for Japanese voice over for cutscenes, improved load times, enhanced control options, better load times, 4K resolution options, and framerates targeting 60 frames per second. The game will launch on August 20 for $69.99 on PS5 and $59.99 on PS4. Reference Link

12:15 EDT Toyota reports June U.S. sales up 39.8% to 207,331 units - Toyota Motor North America reported U.S. June 2021 sales of 207,331 vehicles, an increase of 39.8% on a volume and daily selling rate basis versus June 2020. June 2021 sales of alternative powered vehicles, or APVs, including hybrids, EVs and fuel cells totaled 46,074 vehicles, representing 22.2% of total monthly sales. Toyota division posted June sales of 180,623 vehicles, up 41.6% on a volume and DSR basis. Lexus division posted June sales of 26,708 vehicles, up 29.1% on a volume and DSR basis. For the first half of 2021, TMNA reported U.S. sales of 1,291,879 vehicles, an increase of 44.5% on a volume basis and an increase of 46.5% on a DSR basis.

12:07 EDT Facebook announces 98% U.S. coverage of cloud gaming platform - Facebook said its website: "Last October, we announced the closed beta of our cloud gaming platform to expand the library of mobile games on Facebook, playable instantly, with no installs, wherever and whenever players want. We started with launching a handful of cloud-streamed games on Android and web in select US regions. We've now scaled our infrastructure significantly, and today we're announcing coverage to over 98% of people in the mainland United States. We're on track to hit 100% by fall of this year. We're also beginning our roll out in Canada and Mexico, and will reach Western and Central Europe by early 2022." Reference Link

12:02 EDT Canadian Nuclear Safety Commission informed by Cameco of forest fire near mine - The Canadian Nuclear Safety Commission said via Twitter on Wednesday that, "We have been informed by Cameco Corporation of a forest fire in the vicinity of the Cigar Lake Mine in Northern Saskatchewan. We are monitoring the situation and will provide updates accordingly." Cameco trading has been halted on Thursday, news pending. Reference Link

12:00 EDT Micro Focus falls -14.7% - Micro Focus is down -14.7%, or -$1.11 to $6.42.

12:00 EDT U.S. Silica rises 13.1% - U.S. Silica is up 13.1%, or $1.51 to $13.07.

12:00 EDT Fast Acquisition rises 18.2% - Fast Acquisition is up 18.2%, or $2.15 to $13.96.

11:54 EDT PNC Financial raises dividend 9% to $1.25 per share - The board of directors of PNC Financial declared a quarterly cash dividend on the common stock of $1.25 per share, an increase of 10c per share, or 9%, from the second quarter dividend of $1.15 per share. The dividend will be payable Aug. 5 to shareholders of record at the close of business July 16.

11:09 EDT Cameco trading halted, news pending

11:05 EDT Enterprise Products acquires ethylene storage business from NOVA Chemicals - Enterprise Products Partners and NOVA Chemicals announced that a subsidiary of Enterprise has acquired a wholly owned subsidiary of NOVA Chemicals, which operates an ethylene storage business and trading hub in Mont Belvieu, Texas. NOVA Chemicals, one of the largest merchant ethylene producers and marketers on the U.S. Gulf Coast, will be a long-term storage customer in the Enterprise system. "The acquisition, which gives Enterprise ownership of the largest ethylene market hub in Texas since it was established in 2001, will complement Enterprise's own growing ethylene network in the region. The combined system offers multiple benefits for producers, consumers and traders, such as increased physical connectivity, greater market liquidity and pricing transparency, as well as improved access to Enterprise's ethylene midstream services, including our export terminal and growing Gulf Coast pipeline system," said Chris D'Anna, senior vice president, Petrochemicals of Enterprise's general partner.

11:02 EDT GE Digital joins Airbus and Delta TechOps in Digital Alliance - GE Digital (GE) announced that it joined the aviation Digital Alliance - an expanding partnership initiated by Airbus (EADSY) and Delta TechOps (DAL) in 2019. "Together these aviation leaders combine their respective industry expertise in digital analytics, aircraft systems, and airline and maintenance operations to provide cost savings, network efficiencies and increased fleet availability to 140 commercial aviation operators worldwide already engaged with Skywise Core. GE Digital brings its best-in-class predictive analytics software and extensive aerospace systems engineering expertise to Airbus' Skywise cloud-based open data platform and Delta's operational and maintenance excellence and related predictive models. With GE Digital's added analytics capabilities and systems portfolio covering Airbus as well as non-Airbus OEM aircraft, airlines will further benefit from cross-fleet health monitoring and diagnostics, reliability analysis, and predictive maintenance analytics," GE stated.

10:42 EDT Mazda Motor reports June U.S. sales up 28.7% to 32,605 vehicles - Mazda North American Operations reported total June sales of 32,605 vehicles, an increase of 28.7% compared to June 2020. With 25 selling days in June, compared to the same number of days the year prior, the company posted an increase of 28.7% on a Daily Selling Rate, or DSR, basis.

10:36 EDT GM says 'well positioned' to lead U.S. industry in full-size, mid-size pickups - GM is "well positioned in 2021 to lead the industry in full-size and mid-size pickup sales for the seventh consecutive year," the company said while announcing Q2 U.S. sales results "During the quarter, GM earned 40.6% of the retail market for full-size pickups, up 4.5 percentage points year over year, with more than 237,000 Chevrolet Silverados and GMC Sierras sold in the quarter," GM stated.

10:08 EDT Sun Country says third-party software application outage affecting flights - In an statements posted to its website, Sun Country Airlines said: "Sun Country Airlines is experiencing a temporary third-party software application outage affecting all Sun Country flights, as well as the flights of many other airlines worldwide. Our Operations team is executing our approved manual process and working closely with the FAA to clear flights for takeoff. However, this manual process is causing delays throughout our system. We appreciate the patience of our guests as we work to get them safely on their way as quickly as possible. We are working with our provider's team to resolve the situation as quickly as possible, and it has the full attention of our entire Operations team. We will provide more information as soon as it becomes available. Questions regarding the cause of the disruption or the restoration of the system should be directed to AIMS International." Reference Link

10:02 EDT Blackstone funds acquire majority stake in the Certified Collectibles Group - Blackstone announced that funds managed by its Tactical Opportunities business have agreed to acquire a majority stake in the Certified Collectibles Group in a transaction valuing the company at more than $500M. Mark Salzberg, CCG's founder, and Steven Eichenbaum, CCG's CEO, will retain a significant minority stake. Additional investors in the transaction include Roc Nation; Michael Rubin, founder and executive chairman of Fanatics; SC.Holdings, a growth equity platform; Mastry, founded by Rudy Cline-Thomas; Andre Iguodala; Daryl Morey, President of Basketball Operations for the Philadelphia 76ers; and Main Street Advisors, a leading investment advisory firm to prominent athletes, recording artists, and other leaders across entertainment and business. CCG is a global provider of expert, impartial and tech-enabled services that add value and liquidity to collectibles.

10:00 EDT Nam Tai Property falls -8.3% - Nam Tai Property is down -8.3%, or -$2.30 to $25.41.

10:00 EDT Transocean rises 11.4% - Transocean is up 11.4%, or 52c to $5.04.

10:00 EDT Franklin Covey rises 16.6% - Franklin Covey is up 16.6%, or $5.36 to $37.71.

09:54 EDT Legion Partners' director candidates issue letter to Genesco shareholders - Legion Partners Asset Management, which collectively with the other participants in its solicitation beneficially owns approximately 5.9% of the outstanding common shares of Genesco, announced that its four independent director candidates - Marjorie Bowen, Margenett Moore-Roberts, Dawn Robertson and Hobart Sichel - have issued a letter to shareholders regarding their value-enhancing vision. The letter read, in part, " Each of us agreed to be nominated by Legion Partners earlier this year because we believe Genesco's best days should still be ahead of it. Although the Company has spent many years stagnating and underperforming relative to its peers and relevant indices, we believe that there are an array of issues that can be fixed by an engaged, objective and properly refreshed Board. These issues include: A Value-Destructive Conglomerate Structure; Poor Capital Allocation and Strategic Oversight; Excessive Interlocks Among Directors and Insiders ; Bloated Cost Structure and Sustained Margin Erosion; A Lack of Focus on Operational Excellence at Journeys; Misaligned Executive Compensation . We believe that a Board comprised of impartial individuals with fresh views and the right skills and experience can quickly identify actionable solutions. This is the type of Board that Genesco will have if shareholders elect us. Collectively, we possess extensive corporate governance acumen, capital markets expertise, retail operations experience, e-commerce and digital know-how, and strategic turnaround backgrounds. We also have a deep and practical understanding of best practices for driving growth while implementing environmental, social and governance and Diversity, Equity and Inclusion initiatives...Our ideas, if implemented, could lead to annual earnings of $13 per share, which is a substantial increase from the $5 per share of earnings that Genesco achieved pre-pandemic. We recognize that in order for ideas to turn into actions, there will need to be collegial deliberation of fresh and varying perspectives in the boardroom. That is what we hope to facilitate if we are fortunate enough to be elected to the Board at this year's Annual Meeting."

09:48 EDT Fast Acquisition jumps after Fertitta adds assets to planned merger - Fertitta Entertainment, the parent company of Golden Nugget, and Fast Acquisition (FST), a special purpose acquisition company, announced that they have entered into an amendment to their previously announced merger. According to the amendment, Fertitta has agreed to contribute certain operating businesses not originally included as part of the business combination with Fast for no additional debt. Businesses that will now be contributed to the public company include the Mastro's brand, the Aquariums, the Pleasure Pier, Vic and Anthony's, and a "handful of smaller restaurant concepts," adding a total of 42 incremental business assets. Also, Fertitta will enter into a transaction to acquire the Catch restaurants, including Catch Steak, which restaurant group is already 50% owned indirectly by Tilman Fertitta. In connection with the amendment, Mr. Fertitta will receive additional equity in the NYSE public company which will increase his total equity stake post -closing of the transaction to approximately 72%. According to Tilman Fertitta, "the contribution of the new business assets greatly improves the Company's operating cash flow, provides better assets for organic growth, and significantly deleverages the Company as no incremental debt is being incurred by the Company as part of the revised transaction. Since the rollout of covid vaccinations, the operating results of the incremental assets have been so strong, I decided that I should be focused all in on the Company as I see opportunities for a significant acquisition that would not otherwise be available to the Company without this revised transaction." The amended transaction implies an enterprise valuation for Golden Nugget/Landry's of approximately $8.6B. The enterprise value includes the value of the Golden Nugget Online (GNOG) equity to be contributed to the company, based on an assumed per share trading price of approximately $13.00 for GNOG shares. Shares of Fast Acquisition are up 10%, or $1.17, to $13.00 in early trading.

09:47 EDT Full Truck Alliance falls -6.8% - Full Truck Alliance is down -6.8%, or -$1.38 to $19.00.

09:47 EDT DiDi rises 7.6% - DiDi is up 7.6%, or $1.07 to $15.21.

09:47 EDT Aspen Aerogels rises 10.6% - Aspen Aerogels is up 10.6%, or $3.17 to $33.09.

09:38 EDT Williams completes acquisition of Sequent Energy Management - Williams (WMB) announced it has completed its acquisition of Sequent Energy Management, L.P. and Sequent Energy Canada, Corp. from Southern Company Gas (SO). The acquisition, announced in May, accelerates Williams' natural gas pipeline and storage optimization and marketing growth and increases Williams' gas pipeline marketing footprint to over 8 Bcf/d, with expansions into new markets to reach incremental gas-fired power generation, liquified natural gas exports and future renewable natural gas and other emerging opportunities. "The addition of Sequent Energy Management, including its talented workforce and industry leading platform, complements the current geographic footprint of our core pipeline transportation and storage business," said Alan Armstrong, president and CEO of Williams. "As we continue to take a leadership role towards a clean energy future, Williams sees significant opportunity to better source and deliver responsibly produced, low carbon supplies to domestic natural gas and international LNG customers. Sequent's operational footprint in the U.S. and Canada provides Williams with an enhanced North American perspective of natural gas markets, in turn bolstering the company's natural gas focused strategy, and I'm excited to welcome the Sequent employees to the Williams family."

09:35 EDT Moderna says Recipharm now manufacturing Covid vaccine in France - Moderna and Recipharm confirmed that following the European Medicines Agency's Committee for Human Medicines approval of the Recipharm Monts site on June 11, drug product manufacture of the Moderna COVID-19 vaccine at the site in France has now begun. "We are proud to be working with Recipharm to build industrial production capacity in France in support of Europe's vaccination campaign," said Stephane Bancel, CEO of Moderna. "France is at the heart of European innovation in healthcare and will play an important role in Moderna's strategic growth plan."

09:23 EDT Eagle Bulk Shipping publishes 2021 ESG sustainability report - Eagle Bulk Shipping announced that it has issued its second annual Environmental, Social, and Governance Sustainability Report. The report, which has been prepared in accordance with the Marine Transportation Framework established by the Sustainability Accounting Standards Board, provides an overview of Eagle's strategic priorities and performance with respect to various environmental, social, and governance-related matters.

09:21 EDT Tyler in pact with Florida Certification Board to improve online services - Tyler Technologies announced the Florida Certification Board FCB signed a multi-year contract for Tyler's State Regulatory Licensing and Enforcement software and online portal, implemented on the CAVU eLicense solution. This new partnership demonstrates Tyler's commitment to serving all types of regulatory agencies, including independent, non-profit certification boards. The FCB selected Tyler because of the robust functionality and high level of configurability of the software and its ability to perform more complex connections and operations, as well as Tyler's decades of experience in this area. Tyler's software solution will provide improved online services and ensure a customer-friendly service experience both for certification holders and the general public. This enhanced system will also allow the FCB to meet or exceed the level of transparency and reporting that the Florida legislature requires. "After being through several system implementations and migrations over the past five years, we learned that our requirements and processes for the certifications we issue would be much better supported by a purpose-built regulatory and enforcement solution," said Neal McGarry, president & CEO, Florida Certification Board. "Tyler's regulatory software offers more functionality and a better online experience for our constituents. It will allow us to improve how we serve our certification holders and the public, and is best suited for protecting the health, safety and welfare of the citizens of Florida."

09:18 EDT Anika Therapeutics announces first surgery performed with WristMotion system - Anika Therapeutics announced the limited launch and first surgery performed with Anika's WristMotion Total Wrist Arthroplasty System. The procedure, which is intended to alleviate pain and restore function, mobility, and rotational freedom of an arthritic wrist joint, was completed by Arnold-Peter C. Weiss, M.D. on June 30, 2021. "At Anika, we continue to focus on meaningful advancements in areas with unmet needs as well as market opportunities that will allow patients to remain active and engaged in the activities they love. Preserving motion and native anatomy are core pillars of our innovation philosophy and our R&D roadmap where the WristMotion TWA is a key strategic addition to our portfolio. This is another hand and wrist collaboration with Dr. Arnold-Peter Weiss, who shares our passion for innovation in this space, and has provided us a wealth of design and clinical input into products that we believe will change the treatment algorithms and improve patients' lives," said Steven W. Ek, Vice President of R&D at Anika. "The WristMotion System is a major advancement in total wrist replacement and further solidifies our leadership position in this market while providing an opportunity to pull through other key products in our joint preservation portfolio. We are thrilled that patients will now be able to experience the benefits of this minimally invasive, bone-sparing and motion preserving treatment for wrist pain and arthritis. It doesn't just restore motion, it restores natural motion." The WristMotion TWA System, cleared by the FDA in October 2020, is a modular joint preservation system that replaces both the radial and carpal sides of the wrist joint for patients suffering from rheumatoid arthritis, osteoarthritis, or post-traumatic arthritis. The WristMotion TWA System, along with the WristMotion Hemiarthroplasty device, provides surgeons with multiple treatment options for different stages and severities of wrist osteoarthritis.

09:16 EDT Infrastructure and Energy Alternatives awarded $70M contract in Illinois - Infrastructure and Energy Alternatives announced that the company has been awarded the Big Sky Repower balance of plant project valued at approximately $70M. Vitol, a leading energy company awarded the project to White Construction, a subsidiary of IEA that manages utility-scale renewable energy and heavy civil infrastructure projects. The award is for the repowering of a 240 megawatt utility-scale wind farm in the Bureau and Lee Counties of Illinois. Work on repowering the Big Sky Wind Farm will begin in August 2021 and is expected to be completed in July 2022. IEA will self-perform all of the engineering, procurement and construction needs of the project, including full decommissioning and foundation removal of five wind turbine generators and the repowering of 109 WTGs, including the replacement of nacelles, hubs, blades and adaptor rings. By the end of the construction, it is expected that the project will increase the wind farm's annual output by approximately 60%.

09:14 EDT IMAC launches acute care services for musculoskeletal injuries - IMAC announces the launch of its dedicated acute injury service line. Coinciding with the launch of this service, IMAC will provide physicians, lawyers, and referral sources a toll-free hotline for around-the-clock access to schedule patients with acute sports, accident, and work-related injuries. The acute injury service is available at IMAC Regeneration Center locations in Florida, Illinois, Kentucky, Missouri, and Tennessee, which specialize in providing regenerative, orthopedic, and minimally invasive procedures and non-opioid therapies that are ideally suited to treat acute musculoskeletal injuries often caused by a wide range of accidents. IMAC currently delivers work-related injury rehabilitation services for the United States Department of Labor. "Formalizing the acute injury process is an example of taking a successful service from an acquired practice and implementing it in all IMAC clinics," said Jeff Ervin, IMAC's CEO. "Our goal is to give patients access to the most appropriate care quickly. Our existing infrastructure and talented medical team gives patients and referrers confidence for speedy access to quality care."

09:13 EDT Perpetua Resources' proposed action in NEPA process advanced by Forest Service - Perpetua Resources announced that the United States Forest Service - USFS - is advancing Perpetua Resources' modified proposed action in the National Environmental Policy Act - NEPA - process and updated the permitting schedule for the Stibnite Gold Project. Perpetua Resources' modified proposed action represents refinements to Alternative 2 of the August 2020 Draft Environmental Impact Statement. The refined plan incorporates stakeholder feedback on the DEIS and is designed to reduce the project footprint and improve environmental outcomes. The USFS's decision advances Perpetua Resources' improved and preferred Project design in the NEPA process and sets the Project on a clear path to a final permitting decision. The USFS will eliminate DEIS Alternatives 1 and 3 from further consideration. In order to ensure a full analysis of the refined Project, the USFS plans to issue a targeted Supplemental Draft Environmental Impact Statement and provide the public and cooperating agencies the opportunity to review and comment on the additional analysis. The Project schedule update includes that the SDEIS will be released in Q1 2022, a Final Environmental Impact Statement and draft Record of Decision will be published in Q4 2022, and a final Record of Decision will be issued in the first half of 2023.

09:12 EDT STMicroelectronics, Feig collaborate on contactless product personalization - STMicroelectronics and Feig Electronic have combined their RFID know-how in a time-saving logistics solution that can help cut numerous costs and enhance flexibility for vendors of high-tech products such as smart industrial, consumer, and medical devices. Together the Companies have created a production-ready contactless system capable of personalizing palletized items containing ST's ST25DV NFC dynamic tags in just a few seconds, eliminating the need to power-up or even remove the products from their packaging. With this system, end users can eliminate the costs associated with inline programming and leverage contactless NFC technology to enjoy efficient, economical, and flexible stock-management and logistics.

09:10 EDT GSE Systems to deliver simulation solution for energy utility in Saudi Arabia - GSE Systems announced the sale of a complete simulator solution for a Combined Cycle Gas Turbine plant that belongs to a global energy utility based in Saudi Arabia. This simulator solution will provide true high-fidelity models for operator training and engineering for a global energy company that operates in approximately 70 countries on 5 continents. This new order is valued at $1.2M. The customer is committed to accelerate the transition towards net zero carbon in 2045.

09:09 EDT Nano Dimension, Hensoldt announce joint venture for advancing 3D printing design - Nano Dimension announced that it has formed a partnership with HENSOLDT. The recently formed joint venture entity is named J.A.M.E.S. "Nano Dimension is a leading manufacturer of intelligent machines which 3D-print Additively Manufactured Electronics. HENSOLDT has been using Nano Dimension's DragonFly PRO and LDM 3D-AME printer technology since 2018, to fabricate many innovative "first-of" designs, as 3D-printed circuit boards/AME 3D Hi-PEDs," the company said. HENSOLDT and Nano Dimension have been working together to expand the capabilities of AME 3D Hi-PEDs. By formalizing their cooperation and co-investing approximately $6M in the new joint venture entity, J.A.M.E.S, HENSOLDT is strengthening its commitment to developing the most advanced technology in 3D printing. The joint venture is led by HENSOLDT Ventures, an independent unit within HENSOLDT, which implements and brings to market new technologies and business models for the HENSOLDT Group. Yoav Stern, Chairman of the Board & CEO of Nano Dimension, who will serve as the Chairman of the J.A.M.E.S Board of Directors, stated, "I am confident that the co-investment of a supplier of transformative technologies such as Nano Dimension, and an early innovative, advanced adopter, committed to added value disruption such as HENSOLDT, will produce game changing electronic solutions for both suppliers and users of AME/PE. We are on the verge of a revolution in 3D electronic additive manufacturing and are excited to establish a strong ecosystem to drive the development of AME with HENSOLDT. J.A.M.E.S GmbH establishes a strong foundation for a world-wide network to foster research, innovation and ultimately the development of Hi-PEDs in areas and industries still unexplored."

09:08 EDT Central Garden & Pet acquires D&D Commodities, terms undisclosed - Central Garden & Pet announced that it has acquired D&D Commodities. Headquartered in Stephen, Minnesota, D&D is a provider of bird feed. The addition of D&D's brands will expand Central's portfolio in the bird feed category and further deepen the company's relationship with major retailers. Established in 1987, D&D develops, manufactures and sells food for birds, small animals and wildlife under the 3D, Wild Delight, Better Bird and L'Avian Plus brands. The company operates three manufacturing plants in Stephen, Minnesota, Argyle, Minnesota and Greeley, Colorado and sells to large retailers, farm & feed, garden centers and online.

09:08 EDT Zeta Global elects Jene Elzie to board as Class I director - Zeta announced that Jene Elzie has been elected to the Zeta board of directors as a Class I director, increasing the size of the board to six directors. Elzie is currently chief growth officer at Athletes First Partners Agency, a role she has held since 2018. "Elzie will support the next phase of Zeta's growth and its commitment to helping enterprises thrive in a rapidly changing digital ecosystem," the company stated.

09:07 EDT CSX completes acquisition of Quality Carriers - CSX announced it has completed its previously announced acquisition of Quality Carriers, from Quality Distribution. Financial terms of the transaction were not disclosed. Quality Carriers operates over 2,500 trucks and 6,400 trailers that serve many of the largest chemical producers and processors. "The addition of Quality Carriers enables CSX to extend the reach of its network and gain access to new products, markets, and regions through a unique and competitive multimodal solution that leverages the reach of truck transportation with the cost-advantage of rail-based services," the company said. "We are thrilled to welcome the Quality Carriers team to CSX," said James Foote, president and chief executive officer of CSX. "We strive to provide chemical producers and shippers with the most efficient, cost-effective transportation services possible. By combining CSX's and Quality Carriers' capabilities, we can deliver an unparalleled multimodal solution that will generate substantial value for our customers."

09:06 EDT ViacomCBS to unify U.S., international businesses under leadership structure - ViacomCBS announced that it will unify the company's U.S. and international businesses under a simplified global leadership structure. Effective immediately, Chris McCarthy and Brian Robbins are each promoted to the role of president and CEO, with global oversight for their respective brand groups, MTV Entertainment and Nickelodeon. In addition, George Cheeks, president and CEO, CBS, will expand his role to include responsibility for a global content strategy across ViacomCBS' FTA networks around the world. McCarthy, Robbins and Cheeks will continue to report to Bob Bakish, president and CEO, ViacomCBS, and work closely with Raffaele Annecchino, president and CEO of ViacomCBS Networks International. International brand leadership will be realigned under this new structure. In addition, Dan Cohen, president of ViacomCBS global distribution group, will add distribution of ViacomCBS International Studios content to his group's mandate, which will now oversee all ViacomCBS content licensing and distribution globally. Barbara Zaneri assumes the title of chief program acquisitions officer for ViacomCBS, to reflect her expanded role leading all acquisitions globally across linear, streaming and pay. Zaneri will continue to report to McCarthy and partner closely with leaders across ViacomCBS and VCNI.

09:05 EDT First American announces acquisition of Georgetown Title, no terms - First American Financial announced the acquisition of Georgetown Title. Georgetown Title will become part of the direct operations of First American's largest subsidiary, First American Title Insurance Company, strengthening First American Title Insurance Company's ability to serve customers in Williamson County. Georgetown Title's customers will benefit from access to industry-leading resources and state-of-the-art technology available from one of the nation's largest title and settlement providers. "The Georgetown team has an outstanding reputation in Williamson County and their commitment to teamwork and providing a positive customer experience aligns well with First American's values," said Justin Taylor, vice president and state manager for First American Title's Texas operations. "We are eager to welcome the Georgetown team to the First American family and look forward to bringing added services and resources to their customers in Williamson County, specifically in the thriving communities of Georgetown and Round Rock."

09:04 EDT Jamf Holding completes acquisition of Wandera - Jamf announced it has completed the acquisition of Wandera, a leader in zero trust cloud security and access. This acquisition positions Jamf to help IT and security teams confidently protect devices, data and applications while extending the intended Apple experience through the most robust and scalable Apple Enterprise Management platform in the market. "I am very excited to bring Wandera's Apple-first and Apple-best unified cloud security capabilities into the Jamf platform," said Dean Hager, CEO, Jamf. "We believe the way Wandera has built their solutions provides a significant technical advantage to customers and a superior experience for their end users - directly lining up with our purpose of empowering people with technology that puts them first." "Jamf and Wandera both integrate with cloud identity providers to ensure secure access to company resources. While Jamf currently allows users to leverage their single identity and biometrics to access their Mac and cloud applications, Wandera is a true zero trust network access solution that replaces legacy conditional access and VPN technology. It ensures that after a user authenticates into their device, business connections are secured while enabling non-business applications to route directly to the Internet, preserving end-user privacy and optimizing network infrastructure. For IT, deploying servers, managing certificates, and configuring IP addresses are a thing of the past," the company said. The transaction was completed as expected during Jamf's third quarter 2021 and was subject to customary closing conditions, including required U.S. regulatory approvals.

09:03 EDT Veon exercise its put option to sell stake in Algerian subsidiary Djezzy - Veon has exercised its put option to sell the entirety of its 45.57% stake in its Algerian subsidiary, Omnium Telecom Algerie SpA to the Algerian National Investment Fund, Fonds National d'Investissement. Omnium owns Algerian mobile network operator, Djezzy. The exercise of the option initiates a process under which a third-party valuation is undertaken to determine the fair market value at which the transfer will take place.

09:01 EDT Hyundai Motor America reports total June sales of 72,465 units, up 45% y/y - Hyundai Motor America reported total June sales of 72,465 units, a 45% increase compared with June 2020. This was the highest June sales total in Hyundai history and the fourth consecutive month setting a new monthly record. Hyundai set a new June retail sales record with 66,765 retail sales, up 36%. Retail sales rose for the entire lineup with SUVs (+24%), cars (+64%) and eco-friendly vehicles (+639%), all growing substantially. Eco-friendly vehicles also accounted for 11% of the retail volume. In the second quarter, Hyundai sold 240,005 total (+69%) and 226,094 retail (+69%) units, both all-time Q2 records. The first half also saw new records with 407,135 total (+49%) and 383,564 retail (+55%) sales.

08:50 EDT Forterra acquires Barbour Concrete Company, terms not disclosed - Forterra announced that it has acquired the business of Barbour Concrete Company & Barbour Building Systems, a manufacturer of precast concrete products used in drainage, stormwater, utility and other infrastructure applications. Based in Independence, Missouri, Barbour primarily serves the greater Kansas City metropolitan area. For the past 75 years, Barbour has provided high quality products and service to meet customer needs as well as serving as a leader in the National Precast Concrete Association. Forterra expects to continue operating as Barbour Concrete & Barbour Building Systems for the foreseeable future and believes this acquisition will gain it access to new opportunities for growth in the strong and expanding Kansas City infrastructure and residential markets.

08:38 EDT FuelCell completes site construction of fuel cell project in San Bernardino - FuelCell Energy announced the completion of site construction and commencement of commercial operation for its 1.4 megawatt SureSource 1500 biofuels fuel cell project with the City of San Bernardino Municipal Water Department in California. FuelCell Energy's platform eliminates the need for another flare in California. FuelCell Energy offers the only fuel cell power generation platform approved by the California Air Resource Board for use with on-site biofuels. The commercial operation of this project adds 1.4 megawatts to the Company's generation fleet portfolio, bringing the total to 34 megawatts. Key project highlights include: The SureSource 1500 power plant operates on the City's anaerobic digester gas, which will be treated by the proprietary SureSource Treatment system, cleanly producing electricity and thermal energy to support the operation of the SBMWD water reclamation plant. The SBMWD will purchase the clean electricity produced through a 20-year Power Purchase Agreement. The SureSource 1500 power plant will use methane-rich biogas that would otherwise be flared, wasting energy and producing emissions, to produce hydrogen for the production of clean, renewable, carbon neutral power. The SureSource 1500 power plant provides thermal heat that enhances the water treatment process. The SureSource Treatment system is a proprietary clean up technology optimized by FuelCell Energy's extensive experience with on-site biogas treatment. This system allows FuelCell Energy to clean up biofuel and use it on site without injection into the common carrier gas pipeline. Gas treatment requirements are reduced compared to pipeline injection because of the ability of SureSource fuel cell systems to utilize low-Btu biogas.

08:36 EDT PDS Biotechnology joins Russell Microcap Index - PDS Biotechnology Corporation was added to the Russell Microcap Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective on June 28, according to the FTSE Russell website.

08:36 EDT ProPhase Labs engages CORE IR for investor relations services - ProPhase Labs announced that it has retained CORE IR to assist the Company with investor relations, public relations and shareholder communications services. CORE IR will focus on expanding market awareness for ProPhase and conveying the Company's business model and growth strategies to the institutional and retail investment communities.

08:35 EDT Safe-T to acquire CyberKick for initial consideration of $9.3M - Safe-T Group announced the acquisition of CyberKick. The closing of the transaction is expected next week, subject to certain customary closing conditions, including the delivery of all required documents and approvals, and its cash consideration will be funded with internal cash resources. CyberKick is a provider of Software-as-a-Service security and privacy tools, designed to reduce users' vulnerability to threats while making them more resilient in their online activity, to prevent and defend against a wide spectrum of cyber threats as well as to provide users with control of their accounts and management of access to sensitive data. The acquisition will complement Safe-T's secure access portfolio for organizations with the addition of solutions against known and unknown threats and expand its footprint in the private users' cybersecurity market. According to unaudited results provided to Safe-T, the acquired business generated revenues of approximately $4.2M in 2020 and was profitable. The initial consideration paid on the closing of the transaction, for the sale and purchase of 100% of the equity interest in CyberKick, was a combination of cash, $3.7M, and equity, $5.6M, representing approximately 163 million of Safe-T's ordinary shares - approximately 13.5% of the outstanding share capital post-acquisition. The consideration may be increased by an additional earn-out payment of up to $3M in total, subject to certain revenue targets of CyberKick during the first and second year following the closing of the transaction. Safe-T may decide, at its sole discretion, to pay the earn-out consideration in whole or in part in equity. Safe-T committed to support and boost CyberKick's growth by providing financing of $2.5M in the 24 months following the acquisition. Dawson James Securities, Inc. acted as financial advisor to the Company and provided a fairness opinion to the Company's board of directors in connection with the acquisition.

08:34 EDT MarineMax acquires Nisswa Marine, sees accretion - MarineMax announced the acquisition of Nisswa Marine, a full-service Midwest dealer located in Nisswa, Minnesota. Nisswa generated revenue of over $35M in 2020. The acquisition is expected to be accretive in its first full year. Founded in the 1930's, Nisswa Marine is one of the oldest dealers in the country. Lead by Brent, Jeremy and Steve Wiczek, Nisswa Marine offers brands, including Mastercraft, Supra, Moomba, Chris Craft and Premier Pontoons. The Nisswa leadership team will continue to operate the business.

08:33 EDT Accenture acquires CS Technology, terms undisclosed - Accenture has acquired CS Technology, a technology firm and provider of infrastructure transformation services. CS Technology offers cloud infrastructure engineering capabilities with strengths in the areas of infrastructure and cloud planning, critical facilities design, data center and modern workplace technologies. Terms of the transaction were not disclosed. Established in 1992 and with headquarters in New York, CS Technology has offices in London, Melbourne and Sydney. The company provides a suite of strategy to execution services in the domains of data center, cloud, modern workplace and operating models with a mandate to enhance the return on people, process and technology investments. CS Technology currently serves Fortune 2000 clients across numerous sectors including financial services, retail and pharmaceutical, among others. CS Technology also holds strategic ecosystem partnerships with OEMs, data center providers and major cloud providers. The acquisition of CS Technology adds more than 100 professionals to Accenture with various accreditations in cloud, workplace, project management and engineering.

08:32 EDT DexCom sues Abbott for patent infringement - In a regulatory filing, DexCom (DXCM) disclosed that on June 30 the company initiated litigation against Abbott Diabetes Care (ABT) for infringement of certain of the company's patents. "Abbott previously sued the company for patent infringement in United States District Court for the District of Delaware on August 11, 2005. The parties settled the prior litigation on July 2, 2014 with a settlement and license agreement, which contained a covenant not to sue that expired on March 31, 2021. That covenant has not been extended by the parties. The company is therefore taking steps to protect and enforce its intellectual property rights. The litigation alleges that Abbott's Libre products infringe the company's patents covering its proprietary continuous glucose monitoring technology. The litigation seeks damages and injunctive relief," DexCom stated in the filing.

08:20 EDT Solid Biosciences appoints Roxana Donisa Dreghici as SVP, clinical development - Solid Biosciences announced the hiring of Roxana Donisa Dreghici, M.D. as Senior Vice President, Clinical Development, Caitlin Lowie as Vice President, Communications & IR and Alison Kessler as Vice President, Legal Corporate & IP. Donisa Dreghici most recently was the Global Development Lead/Associate Group Medical Director, Neuroscience for F. Hoffmann La Roche in Basel, Switzerland. Lowie was most recently Senior Director, Communications and Strategic Growth Initiatives at Stallergenes Greer. In her role at Solid Biosciences, Ms. Lowie will lead the development, implementation and execution of an integrated and innovative IR strategy. Additionally, she will be responsible for the corporate communications strategy, ensuring alignment with the overall corporate strategy and IR goals. Kessler joined Solid Biosciences as interim general counsel in November 2020. In her new role with the Company, Ms. Kessler will be responsible for providing strategic advice on matters related to Solid's IP portfolio, business development endeavors, and a variety of other contracting and corporate matters.

08:18 EDT Catalyst Biosciences to host R&D day on CB 4332, complement programs - Catalyst Biosciences announced that it will host a research and development day on its protease medicines platform focusing on the regulation of complement including CB 4332 on Monday, July 19, 2021 at 12:00 pm Eastern Time. The Catalyst Biosciences R&D Day will feature a presentation by Key Opinion Leader Filomeen Haerynck, M.D., Ph.D., University of Ghent, Belgium, who will discuss the clinical phenotype, current treatment landscape and unmet medical need in treating patients with complement factor I deficiency and other complement system disorders. The event will also feature a presentation by Catalyst Biosciences' management team on the company's upcoming clinical trial and the benefits of addressing the complement pathway with its protease medicines platform. The Catalyst team will discuss the planned commencement of screening and natural history of disease studies in mid-2021 followed by a Phase 1/2 study for CB 4332 in 2022. The screening study is designed to identify people with a CFI deficiency by assessing circulating levels of CFI. The natural history of disease study will follow up and assess these patients for clinical outcomes, biomarkers of complement dysregulation as well as safety and effectiveness of their current treatments in preparation for the clinical development program of CB 4332. Catalyst's complement portfolio is led by the development candidates CB 4332 and CB 2782-PEG, originating from the company's internal discovery platform, which has generated a rich pipeline of leads. CB 4332 is an engineered CFI protease with the potential to become a therapy addressing multiple complement related disorders. CB 2782-PEG is a potential best-in-class C3 degrader product candidate in preclinical development for the treatment of dry AMD that Catalyst has licensed to Biogen. Catalyst has several engineered protease programs in discovery or early non-clinical development. These programs all target diseases caused by deficient regulation of the complement system.

08:16 EDT Beam Global forms Equity Oversight Committee - Beam Global announced that it has instituted a new equity oversight governance model at the board level. The company has created an independent Equity Oversight Committee within the Board of Directors to assess all future uses of equity. The EOC is comprised of a committee of independent board members chaired by Nancy Floyd. Nancy Floyd is also currently the chair of the Audit Committee and has over three decades of governance, financial and M&A experience. The EOC's mandate is to consider any uses of equity proposed by management or members of the board. The EOC is made up entirely of independent board members and will have authority over whether or not a proposed use of equity is submitted to the full board for a vote. This new and innovative governance mechanism ensures that only uses of equity which have been vetted by the independent EOC can pass to the full board for a vote for approval or denial.

08:16 EDT Entasis Therapeutics presents clinical data on ETX0462 - Entasis Therapeutics announced the presentation of preclinical data on ETX0462, a novel diazabicyclooctane with antimicrobial activity against multidrug-resistant, or MDR, Gram-negative and biothreat pathogens, at the 2021 World Microbe Forum. ETX0462 potentially represents the first new antibiotic class in 35 years to treat MDR Gram-negative and biothreat infections. At the World Microbe Forum, Entasis scientists presented their approach to the discovery of ETX0462 that incorporated Structure-Porin Permeation Relationships and Structure-Based Drug Design to identify key principles for penicillin-binding protein inhibition and corresponding antimicrobial activity against contemporary MDR Gram-negative and biothreat isolates, including P. aeruginosa, K. pneumoniae, S. maltophilia, E. coli, B. anthracis, Y. pestis, F. tularensis and Burkholderia spp. Entasis scientists further demonstrated that the activity of ETX0462 was unaffected by all four Ambler classes of beta-lactamases and has a low propensity for resistance emergence due to its ability to permeate bacterial cells through multiple porins and inhibit several PBPs. "ETX0462 is the latest product candidate to emerge from our discovery platform and the first example of a novel class of agents targeting the established mechanism of beta-lactam antibiotics without being susceptible to the most common beta-lactam resistance mechanism, beta-lactamases," commented Ruben Tommasi, CEO at Entasis. "We look forward to continuing our successful collaboration with CARB-X as we progress ETX0462 towards the clinic."

08:14 EDT Walgreens Boots Alliance jumps over 2% after Q3 earnings beat, raised guidance - Shares of Walgreens Boots Alliance are up over 2% at $53.70 in pre-market trading after the company reported a Q3 earnings beat and also raised its FY21 EPS guidance to about 10% from mid-to-high single digit growth. The updated guidance implies expected FY21 EPS of about $5.21 vs. $4.69 consensus.

08:13 EDT Aileron Therapeutics announces initiation of trial of ALRN-6924 - Aileron Therapeutics announced that it has initiated a randomized, double-blind, placebo-controlled clinical trial in the US and in Europe of ALRN-6924 as a chemoprotective agent to treat patients with non-small cell lung cancer, or NSCLC, undergoing chemotherapy. Aileron plans to enroll 60 patients with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin plus pemetrexed with or without immune checkpoint inhibitors in this Phase 1b trial. Aileron is developing ALRN-6924 to selectively protect healthy cells in patients with cancers that harbor p53 mutations to reduce or eliminate chemotherapy-induced side effects while preserving chemotherapy's attack on cancer cells, a concept known as chemoprotection. Manuel Aivado, M.D., Ph.D., President and CEO of Aileron, said, "This NSCLC trial represents important progress in our clinical development strategy, as it involves a p53-mutated cancer indication that affects one of the largest cancer patient populations, and it is our first randomized, double-blind, placebo-controlled trial. In addition, the trial is designed to help us further advance our ultimate goal of pursuing a tumor-agnostic indication for ALRN-6924 as a chemoprotective agent for patients with p53-mutated cancers regardless of type of cancer or chemotherapy, with the potential to help millions of patients." Primary endpoints are the proportion of treatment cycles free of severe hematological and other toxicities, including Grade greater than or equal to 3 neutropenia, Grade greater than or equal to 3 thrombocytopenia, Grade greater than or equal to 3 anemia, Grade 4 neutropenia and febrile neutropenia, as well as duration of Grade 4 neutropenia. An additional primary endpoint is the proportion of completed treatment cycles without chemotherapy dose reduction or without the use of growth factors or transfusions. Other endpoints include the proportion of patients with National Cancer Institute Common Terminology Criteria Adverse Events Grade 3/4 treatment-emergent adverse events, quality of life, overall response rate, and progression-free survival. Aileron anticipates reporting first interim safety data from the trial late in the fourth quarter of 2021 and full results in mid-2022.

08:12 EDT Harsco announces Clean Earth facility's ability to manage aerosol cans - Clean Earth announces that its Morgantown, West Virginia location is immediately able to process and recycle aerosol cans in accordance with the U.S. Environmental Protection Agency Aerosol Cans as Universal Waste Rule that has now gone into effect in West Virginia, effective today. The Aerosol Cans as Universal Waste Rule allows aerosol can waste to be managed as universal waste under the federal Resource Conservation and Recovery Act hazardous waste rules instead of classifying them as hazardous waste. Some of the objectives of this rule are to promote recycling of aerosol cans, thereby reducing the number being sent to landfills, as well as to ease regulatory burdens on retail stores and others discarding aerosol cans. The EPA finalized this new rule on November 15, 2019 and published it in the Federal Register on December 9, 2019. The rule became effective on February 7, 2020 in non-authorized states but had to be adopted in authorized states such as West Virginia. Clean Earth's hazardous waste facility in Morgantown is a Part B permitted Treatment, Storage, and Disposal Facility capable of receiving a large variety of hazardous and non-hazardous wastes in drums, totes and bulk. The treatment, disposal and recycling process combine leading edge concepts with proven technology to provide reuse and recycling options without higher costs. The Morgantown facility's capabilities include the processing and recycling of aerosol cans. With the ability to batch process and isolate equipment systems, Clean Earth can process waste and non-waste materials based on customer needs.

08:10 EDT Achilles Therapeutics enroll first patient in ongoing Phase I/IIa study in NSCLC - Achilles Therapeutics announced that the first patient in the United States has been enrolled in the company's ongoing Phase I/IIa CHIRON clinical trial. CHIRON is an open-label, multi-center Phase I/IIa trial evaluating the safety, tolerability, and activity of clonal neoantigen T cell, or cNeT, therapy as a single dose in adult patients with advanced metastatic non-small cell lung cancer, or NSCLC. This first US patient was enrolled at the Moffitt Cancer Center in Tampa, FL where Dr. Benjamin Creelan is the Principal Investigator. CHIRON is now open at 10 sites in the UK, EU and the US. "We are delighted to have taken our cutting-edge, cNeT platform into the US with the successful enrollment of the first patient at the Moffitt Cancer Center in our ongoing CHIRON study," said Dr Iraj Ali, CEO of Achilles Therapeutics. "With our cNeT platform we prospectively target patient-specific clonal neoantigens and are able to generate comprehensive characterization including the dose of the active cNeT component for each product. We look forward to providing an update from 10 patients across our CHIRON and THETIS studies in NSCLC and melanoma, respectively, in the fourth quarter of this year where we will present data highlighting a basis for our proposed potency assay." CHIRON is expected to recruit approximately 40 patients with advanced unresectable or metastatic NSCLC. The primary objective of the trial is to assess the safety and tolerability of cNeT. Clinical efficacy will be evaluated as a secondary measure. Additional data evaluating cNeT persistence, phenotype, and functionality will be reviewed while also exploring potential biomarkers of clinical activity and factors affecting response. This will include analysis of patient samples using a bespoke plasma ctDNA assay.

08:08 EDT Adamis Pharmaceuticals sends letter to shareholders regarding board memebers - Adamis Pharmaceuticals issued the following letter to stockholders: "The Board of Directors (the "Board") appreciates your continued investment in Adamis Pharmaceuticals Corporation ("Adamis" or the "Company" or "we"). The Board also appreciates the feedback that many stockholders have provided in recent weeks. As we work to position Adamis for long-term success, please trust that this input will be carefully assessed and factored into our go-forward plans. We are writing to you today to once again urge you to vote to re-elect all five members of the Board at the Company's upcoming Annual Meeting of Stockholders (the "Annual Meeting") on July 16, 2021. In our view, maintaining boardroom continuity can help the Company achieve the following: Support the ongoing Food and Drug Administration ("FDA") review of our ZIMHI(TM) New Drug Application. Advance our Phase 2/3 trial for examining the effects of Tempol on COVID-19. Support ongoing efforts to obtain government funding for Tempol. Advance the Investigational New Drug for Tempol's use in radiation dermatitis. Demonstrate a further increase in SYMJEPI(R) sales. Maintain a strong capital position and healthy balance sheet. Prioritize progress across our entire product pipeline... Mr. Hammann initially demanded a lucrative and unjusitified paid consulting agreement - which would have been paid for with stockholders' capital - before he was even a stockholder of the Company. Mr. Hammann threatened to make books and records demands and to run a campaign against the Board if we did not quickly agree to award him the demanded consulting agreement. Mr. Hammann has no operating experience in the biotechnology or pharmaceutical sector. Mr. Hammann has no experience as a director or executive of a public company. Mr. Hammann has a history of filing serial lawsuits and being a vexatious litigator. Mr. Hammann submitted an untimely and invalid notice of director nominations. His nominations will not be accepted at the Annual Meeting. Mr. Hammann unsuccessfully sued the Company in an attempt to delay the Annual Meeting and forced us to expend precious stockholder capital on fending off litigation. Mr. Hammann has no plan for the Company. We hope stockholders recognize that supporting Mr. Hammann's misguided campaign would be akin to taking what we believe is a major risk. Rather than support a litigious stockholder that is waging a costly and distracting battle with the Company, we urge you to reject his efforts by voting to re-elect your current Board. Once again, we thank you for your investment in Adamis. We firmly believe that the Company is on the right path now that we have tangible pipeline momentum. Vote on the WHITE proxy card to elect our full five-member slate and help us sustain the Company's progress."

08:08 EDT Magal Security initiates steps to change name to Senstar Technologies - Magal Security announced the successful completion of its planned divestiture of the company's Integration Solutions Division and that it has initiated steps to change its name to Senstar Technologies. In connection with the completion of the divestiture and the company's desire that its name and brand will echo its focus on its products division, the company announced that it plans to change its name to Senstar Technologies and starting July 1 to rebrand its activities under the brand name Senstar Technologies. The name change is subject to approval by shareholders.

08:06 EDT Foresight Autonomous says Eye-Net, V-tron partner for pilot project - Foresight Autonomous Holdings announced that its wholly owned subsidiary, Eye-Net Mobile Ltd., will collaborate on a pilot project with V-tron. V-tron will evaluate the Eye-Net Protect solution for possible integration into its onboard units and application services in order to enhance the value of its innovations offering and prevent accidents by connecting road users and alerting about potential collisions in real time.

08:05 EDT Taoping appoints Huan Li as CMO, provides business updates - Taoping provides an update of its business and announces the promotion of Huan Li, current director of Digital Culture Business Division, to concurrently serve as the company's Chief Marketing Officer, or CMO. Li will oversee all product marketing, brand strategy, direct and digital marketing, data analytics and marketing operations. Business Updates: As previously disclosed, on June 9, 2021, the company closed its acquisition of Taoping New Media. The company expects to book advertising revenues starting from June 2021. The company's previously-announced acquisition of Render Lake is currently being reviewed by relevant Canadian authorities and the company will work diligently to cooperate fully with the authorities to complete the review as soon as possible. The company's NFT business continues as planned and the company currently does not expect any negative impact from China's recent ban on digital asset mining on its NFT business. The company's G Cloud Data Centers in Dongguan and Hong Kong are running smoothly. In the meantime, the company is actively seeking overseas locations to expand footprints of Taoping G Cloud Data Centers.

08:05 EDT HP Enterprise to acquire Zerto for $374M, sees accretion - HP Enterprise announced that it has entered into a definitive agreement to acquire Zerto, a cloud data management and protection company, in a transaction valued at $374M. The company said this acquisition expands HPE GreenLake and continues to deliver on HPE Storage's shift to a cloud-native, software-defined data services business. Zerto's journal-based continuous data protection technology includes disaster recovery, backup, and data mobility in a single cloud data management and protection software solution that spans on-premises, hybrid, and multi-cloud environments. Zerto will be available aaS through HPE GreenLake and Data Services Cloud Console. HPE is acquiring Zerto for $374M in cash. The company plans to fund the acquisition through cash on its balance sheet. The transaction is expected to contribute more than $130M in run-rate revenue at software gross margins. Approximately one-third of the revenue is expected to contribute to HPE's aaS annualized revenue run-rate. The acquisition is also expected to be accretive to non-GAAP operating profit and earnings starting in FY 2023. Zerto's management team is joining HPE following the close of the transaction, which is expected to occur in Q4 of HPE's FY21, subject to regulatory approvals and other customary closing conditions. After the transaction closes, Zerto will be organized under HPE Storage, reporting to Tom Black, senior VP and general nanager.

08:04 EDT Broadridge acquires ECS assets from Jordan & Jordan - Broadridge announced that it is further enhancing its regulatory compliance capabilities for broker-dealers with the acquisition of the cloud-based Execution Compliance and Surveillance Service assets from Jordan & Jordan. The solution provides a combination of surveillance and regulatory reporting as well as compliance consulting capabilities for US regulations. The acquisition enables Broadridge to further extend its strategic regulatory reporting capabilities as well as add compliance and regulatory reporting consulting capabilities. The solution allows broker-dealers to more effectively comply with regulations such as SEC Rules 605/606 and Consolidated Audit Trail and strengthens their capabilities around best execution, trade surveillance and the detection of fraud-based manipulative activity. It also enables clients to monitor the effectiveness of their required policies and procedures and provide detailed records to demonstrate a commitment to ongoing surveillance.

08:03 EDT Celsion announces commencement of enrollment in Phase 1 study of ThermoDox - Celsion GmbH, a wholly owned subsidiary of Celsion, a clinical-stage biotechnology company, announces commencement of enrollment in Oxford University's Phase I PanDox study with ThermoDox in conjunction with Focused Ultrasound in patients with pancreatic cancer. ThermoDox is Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin. This investigator-led study sponsored by the University of Oxford and supported by the National Institute for Health Research Oxford Biomedical Research Centre has now received ethics, MHRA and institutional R&D approval to commence. The primary endpoint of the two-arm 18-subject PanDox study is enhanced uptake of doxorubicin in pancreatic tumors using ThermoDox and Focused Ultrasound, compared to systemic delivery of free doxorubicin. ThermoDox will be administered intravenously in 12 patients with non-resectable pancreatic ductal adenocarcinoma and locally activated by focused ultrasound-mediated hyperthermia. This will be compared to conventional systemic delivery of doxorubicin without FUS in 6 patients. Secondary endpoints include: comparing radiologically assessed tumor activity and response with ThermoDox and FUS to free drug alone; examining the impact on patient symptoms of ThermoDox plus FUS; and assessing the safety profile of both FUS and ThermoDox. The PanDox study is expected to be completed by December 2022 and is similar in design to Oxford's 10-patient TARDOX study, which demonstrated that ThermoDox plus focused ultrasound increased doxorubicin tumor concentrations by up to 10-fold and enhanced nuclear drug uptake in patients with liver tumors.

08:02 EDT Amyris signs exclusive license with Nant Africa - Amyris announced that it has signed an exclusive license with Nant Africa relating to the development and use of the RNA COVID vaccine Amyris developed in coordination with the Infectious Disease Research Institute. The license and collaboration with Nant Africa is expected to generate several million dollars in near term upfront and milestone payments, and also includes long term royalties for the use of the Amyris and IDRI technology on the African continent. The license includes the funding of human clinical trials, which upon successful completion are expected to be followed by the production and scaling of the vaccine in South Africa with a target of reaching patients by the end of this year.

07:58 EDT Naaptol selects EbixCash for managing customer care operations - EbixCash Private announced that India's tele-shopping and one stop online shop Naaptol, has selected EbixCash's BPO Division - EbixCash Global Services as its Customer Care Operations partner for the East Region. Naaptol is a free to air television and online network that has emerged as the the No.1 home shopping company of India, while specializing in televised home shopping. The deal involves EbixCash deploying a number of centers across multiple cities to optimize and manage Naaptol's Customer Care Operations.

07:36 EDT Encompass Health to build 40-bed rehabilitation hospital in Wisconsin - Encompass Health plans to build a freestanding, 40-bed inpatient rehabilitation hospital in Fitchburg, Wisconsin, a suburb of Madison. The hospital, which is expected to be named Encompass Health Rehabilitation Hospital of Fitchburg, will be located at the southeast corner of South Fish Hatchery Road and Nobel Drive. It is expected to begin serving patients in 2023. It will serve patients recovering from major illnesses and injuries including strokes and other neurological disorders, brain injuries, spinal cord injuries, amputations and complex orthopedic conditions.

07:33 EDT Marimaca Copper announces update on exploration work at Roble Target - Marimaca Copper is pleased to provide an update on the ongoing exploration work being completed, ahead of drilling, at the Roble Target. Roble is located less than 3km to the northeast of the Company's flagship Marimaca Oxide Deposit, and mineralization may extend over 3km of potential strike. The commencement of drilling at Roble has been delayed primarily because the Company elected to expand the drilling program at the Mercedes Target based on encouraging mineralization observed in drilling, but also due to some delays caused by COVID restrictions. Highlights: Additional rock chip reconnaissance sampling at Roble has materially expanded the footprint of outcropping oxide mineralization; Mapped outcrop extends further north at Roble and south and east at Pele; Extends strike potential to over 3km with widths at surface ranging from 300m to over 500m; Three discrete areas of consistently outcropping mineralization, each extending over approximately 600m by 400m, separated by gravel and sand cover ; Potential for connection of the larger Roble system through these covered areas; Geophysics identified the continuation at depth of significant regional structures which control the location of mineralization in the Marimaca district; Interpreted structures are strongly coincident with surface trends of outcropping Cu oxide mineralization with greater than 0.1% CuT; Drilling to commence imminently at Roble with an initial twelve-hole reverse circulation discovery drilling program; The Company has expanded the RC drilling campaign at Mercedes from nine holes to eighteen holes due to encouraging mineralization intersected; Resultant delay to the commencement of drilling at Roble, which is now expected during July; Additional rigs planned for 2H 2021 based on expanded exploration programs at Marimaca Depth Extensions, Cindy, Mercedes and Roble. Roble is located less than 3km to the northeast of the Company's flagship Marimaca Oxide Deposit, within the north-north-east trending Roble Fault System. This is a splay off the regional scale Naguayan Fault System, which is an important control for mineralization at the MOD. Roble is associated with a large magnetic anomaly previously identified in the regional, high-resolution, drone mounted magnetics survey. The Company has subsequently completed surface exploration work including rock grid geochemical sampling, reconnaissance mapping and outcrop sampling which defined a large copper-in-rock anomaly and also highlighted the significant extent of outcropping copper oxide mineralization at the surface.The initial exploration work and subsequent reconnaissance mapping and sampling of outcropping oxide mineralization has defined three distinct zones, each extending approximately 600m along strike by 400m across strike. These zones are separated by post mineralization gravels and sands and the Company believes there is the potential for them to be connected under the areas of cover. Following the success of the initial surface exploration work, the Company engaged GRS Geophysics to complete two 2.5km Induced Polarization surveys for a total of 5km of survey, with one line located in the central area, the other approximately 750m to the north, on the northern part of the area of interest. Both lines show attractive coincident resistivity and chargeability anomalies associated with the high magnetic response and clearly highlights the regional scale of Roble Fault System, which the Company believes could be important for controlling copper mineralization in the area. Furthermore, the geophysical anomalies appear to be strongly coincident with the outcropping copper mineralization mapped in the reconnaissance work, both of which follow the broader northerly trend of the Roble Fault System. Preparation of drill pads and associated infrastructure at Roble is currently underway and the Company expects to be drilling the target during July 2021. The Company will complete an initial twelve-hole RC drilling program to test key targets at Roble, Nepal and Pele.

07:16 EDT Ansys selected by ITER Organization for plant risk management - Ansys is collaborating with the ITER Organization to optimize EM structure design and performance for the ITER nuclear fusion plant. Through a new multi-year agreement, Ansys will work with ITER engineers to improve project risk management, streamlining system development and meeting critical safety requirements. ITER engineers leverage Ansys simulation solutions to economically design EM structures.

07:15 EDT Hudson Capital announces FreightHub launch of EDI interface - Hudson Capital announced that FreightHub launched its Electronic Data Interchange interface. EDI is a system or method for exchanging business documents with trading partners, such as suppliers, customers, carriers, 3PLs, or other supply chain connections. EDI optimizes business processes by replacing manual processes such as mail, fax, and e-mail with electronic exchanges of business transactions between two companies that may use vastly different internal business systems.

07:14 EDT Glass Lewis recommends Baudax Bio shareholders vote for additional shares - Baudax Bio announced that Glass Lewis & Co. has recommended that Baudax Bio shareholders vote "FOR" Item 1 set forth in its Definitive Proxy Statement filed with the Securities and Exchange Commission on June 14, 2021 in connection with its Special Meeting, which seeks to amend Baudax Bio's Amended and Restated Articles of Incorporation to increase the number of authorized shares of common stock from 100 million shares to 190 million shares. The Special Meeting will be held on July 13, 2021 at 9:00 a.m. ET. Glass Lewis & Co. and Institutional Shareholder Services Inc. are independent proxy advisory firms and do not have any business relationship with Baudax Bio. Baudax Bio did not engage or compensate either firm for its analysis or recommendations. Baudax shareholders are urged to vote as Glass Lewis & Co. and Institutional Shareholder Services Inc. recommend by voting "FOR" the proposed increase in authorized shares and the adjournment of the Special Meeting of shareholders.

07:13 EDT Concert Pharmaceuticals to present CTP-543 update - Concert Pharmaceuticals will present an update from its ongoing open label, long-term extension study of the investigational medicine CTP-543 in patients with moderate to severe alopecia areata, an autoimmune disorder that results in patchy or complete hair loss. The data show that, relative to previous Phase 2 study results of CTP-543, hair regrowth assessed by the Severity of Alopecia Tool, or SALT, was maintained or improved in the great majority of patients through one year of continuous dosing with 12 mg twice-daily of CTP-543. Approximately 57% of participants receiving 12 mg of CTP-543 twice-daily following 52 weeks of dosing achieved a clinically-meaningful SALT score of 20 or less. Dosing in the long-term extension study is ongoing, and patients completing the ongoing Phase 3 THRIVE-AA trials are eligible to enroll in the study. These data will be presented virtually during the virtual JAK Inhibitors Drug Development Summit. CTP-543 has been generally well tolerated in the long-term extension study with only 4 of the 158 subjects entering the study discontinuing due to adverse events to date. Adverse events are consistent with those previously reported in the Phase 2 trials. Clinical labs for key hematology parameters appear stable across the long-term extension study relative to end of treatment in the Phase 2 trials.

07:11 EDT DSP Group, Alango announce availability of eVCP on DBMD7 processor - DSP Group and Alango Technologies announced the availability of Alango's Extended Voice Communication Package on DSP Group's DBMD7 SmartVoice processor. The combination allows providers of high-performance voice conferencing systems to quickly develop solutions for a rapidly evolving unified communications market that demands the best in voice clarity and system flexibility.

07:10 EDT EyePoint announces new Category III CPT Code for DEXYCU - EyePoint Pharmaceuticals announced that the American Medical Association Current Procedural Terminology Editorial Panel accepted the addition of a new Category III CPT code, 0X78T for the administration of a drug into the posterior chamber of the anterior segment of the eye, effective January 1, 2022, providing an opportunity for a reimbursement pathway for the administration of DEXYCU.

07:09 EDT Alpine Income Property completes portfolio acquisition from CTO Realty Growth - Alpine Income Property Trust (PINE) announced it closed its previously announced acquisition of six high-quality net lease retail properties for a combined purchase price of $44.5 million from CTO Realty Growth (CTO) on June 30, 2021. The CTO Portfolio consists of properties net leased to leading national retailers such as Lowe's, Walgreens, Harris Teeter and Big Lots, with more than 60% of annualized base rent coming from properties leased to, or with leases guaranteed by investment grade-rated entities. All six of the properties in the CTO Portfolio are within metropolitan statistical areas that have populations over one million people, including locations in close proximity to Charlotte, NC; Seattle, WA; Washington, DC; Houston, TX; Phoenix, AZ; and Orlando, FL. As part of the CTO Portfolio acquisition, the Company assumed an existing $30.0 million secured mortgage, which bears a fixed interest rate of 4.33%. The Loan matures in October 2034 and is prepayable without penalty beginning in October 2024. With the closing of the CTO Portfolio, the Company has now completed the acquisition of the seven net lease retail properties from CTO Realty Growth, Inc., which were previously announced on April 6, 2021.

07:08 EDT NGM, Merck amend collaboration to focus on medicines for retinal, CVM diseases - NGM Biopharmaceuticals (NGM) announced that the company has entered into an amended and restated agreement with Merck (MRK) to extend their ongoing collaboration through March 2024 but with a narrower scope. NGM disclosed in March 2021 that NGM and Merck were negotiating modifications to certain terms of the agreement to better address their respective evolving priorities. Going forward, the collaboration will focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck retains an option to license those programs being advanced under the amended collaboration. NGM gains worldwide rights to its disclosed oncology portfolio, as well as all preclinical, and current and future research, assets falling outside of the amended collaboration's narrower scope, subject to a low single digit net sales royalty to Merck The amended collaboration's primary focus on retinal and CVM diseases builds upon progress with NGM621 and MK-3655, both discovered by NGM under the collaboration. NGM621, an anti-complement C3 antibody, is currently being evaluated in the NGM-led Phase 2 CATALINA study in patients with geographic atrophy. MK-3655, an FGFR1c/KLB agonistic antibody previously licensed by Merck, is currently being evaluated in the Merck-led global Phase 2b study in patients with non-alcoholic steatohepatitis (NASH). NGM will pursue further research and development on two undisclosed retinal targets, as well as CVM targets initially focusing on heart failure. NGM has agreed to work exclusively with Merck in heart failure during the remaining collaboration term. Merck retains an option to license assets directed to targets that are developed by NGM within the scope of the amended collaboration at proof-of-concept or at earlier points as specified in the amended collaboration. NGM's currently disclosed oncology product candidates, all derived from the company's in-house discovery engine, are now wholly owned by NGM and include: NGM120, a GFRAL antagonistic antibody in Phase 2 study for the treatment of metastatic pancreatic cancer and cancer-related cachexia; NGM707, an anti-ILT2/ILT4 dual antagonist antibody; and NGM438, a LAIR1 antagonist antibody. In addition, NGM now has full rights to existing preclinical and research assets, as well as any future assets resulting from its in-house discovery engine, in each case that fall outside of the amended collaboration's narrower scope. NGM will be funding these programs going forward. Under the terms of the amended collaboration, Merck will provide an aggregate of approximately $120 million in research and development funding to NGM through March 2024, including $86 million for the period from April 2021 through March 2022, plus additional potential option payments if Merck exercises any license option. The amended collaboration is in place through at least March 2024, with possible extensions for each of the various programs to allow NGM or Merck to complete ongoing development. NGM has committed to advancing an undisclosed ocular program to a potential IND submission, utilizing its own funding after March 2022. Economics for programs for which Merck exercises its license option are unchanged from the original collaboration terms. Prior to Merck initiating any Phase 3 study of a program licensed by Merck, NGM may elect to receive milestone or royalty payments or, in certain cases, co-fund development and participate in a global cost and profit share arrangement of up to 50%. NGM also has the option to participate in the co-promotion of any co-funded program in the United States.

07:05 EDT Acuity Brands reaffirms commitment of 100M metric tons of carbon reduction - At a sales conference during the third-quarter 2021, the Company committed to a goal of 100 million metric tons of carbon reduction by 2030 through the sales of LED luminaires, controls, and building management systems, replacing older technologies in existing buildings and new construction. On July 1, 2021, the Company issued the 2020 Acuity Brands EarthLIGHT Handprint Report: Lighting the Way Toward Net-Zero on its website. The report evaluates the net environmental impact of its products at the point of use, incorporating both the environmental costs of using its products and the environmental benefits of removing older, less-efficient technology.

07:04 EDT Acuity Brands expects to close OSRAM Digital Systems acquisition on July 1 - One June 4, 2021, the Company announced that it has signed a definitive agreement to purchase ams OSRAM's North American Digital Systems business. This acquisition is intended to enable the Company to enhance our LED driver and controls technology portfolio and accelerate our innovation, expand our access to market through a more fulsome OEM product offering, and give us more control over our supply chain. The transaction is expected to close by end of day on July 1, 2021.

07:02 EDT DHI Group completes spinoff of eFinancialCareers - DHI Group has transferred majority ownership of its eFinancialCareers business, a financial services career site, to eFC's management team. DHI will retain a 40% equity interest in eFC and have board representation. Starting with Q2, DHI Group will report its financial results in the statements of operations excluding eFC from continuing operations.

07:00 EDT Wabash sells Extract Technology to Dietrich Engineering - Wabash announced the sale of Extract Technology to Lausanne, Switzerland-based Dietrich Engineering Consultants, a portfolio company of Berlin, Germany-based capiton AG. Extract Technology, based in Huddersfield, U.K., is a worldwide supplier of containment and aseptic systems for the pharmaceutical, healthcare, biotech and chemical markets. Extract Technology joined Wabash National in 2012 as part of the Walker Group Holdings acquisition. Extract Technology represented approximately $22M of sales in 2020 and was reported within Wabash National's Diversified Products Group segment. The sale closed June 30, with Extract Technology continuing operations under the ownership of DEC.

06:52 EDT Genesco issues statement regarding Legion investor presentations - Genesco issued the following statement: "Legion Partners Asset Management LLC ("Legion") and their director slate recently issued two investor presentations consisting of collectively over 200 pages of misinformation, misleading claims, and superficial suggestions, as well as a press release with inaccurate assertions regarding Genesco's commitment to ESG and DE&I, which the Company believes demonstrate a lack of understanding of Genesco's business and the industry and a disregard for long-term value creation. Legion chooses to ignore the hard work that Genesco has already done to address the changing retail environment, as well as its recent results which demonstrate that the Company's strategic plan is working. Genesco has been undergoing a series of transformations since 2019, including at the Board and management level, to execute on a new footwear focused strategy. Under the leadership of lead independent director Matt Diamond, and CEO Mimi Vaughn, Genesco put in place a new six-pillar strategy that is generating results as demonstrated by the Company's recent performance - including delivering compelling results during the pandemic, a time when many others in the industry struggled, as well as kicking off a strong start to FY2022. Legion's public campaign is focused on disrupting the work that is continuing to take place to drive value. Accordingly, Genesco believes it is imperative to set the record straight for shareholders... Since 2016, Genesco's compensation proposals have been supported by both ISS and Glass Lewis and averaged 95% of shareholder support through say-on-pay votes. Genesco's compensation program rewards management for creating sustainable shareholder value by maximizing net operating earnings less the cost of capital used to produce those earnings and also encourages the return of capital to shareholders - demonstrating strong shareholder alignment. It is a thoughtful plan design that incentivizes performance while protecting shareholder interests, and the Board continuously reviews it to ensure Genesco is driving performance and shareholder value creation. Legion's flawed evaluation of compensation is an effort to distract from the overwhelming support these programs have received. Genesco shareholders are encouraged to review Genesco's investor presentation for a comprehensive update on the Company's track record of execution, strong footwear focused strategy, and fit-for-purpose Board of Directors. The presentation and additional information can be found at www.GenescoDrivingValue.com. Most importantly, Genesco strongly urges shareholders to vote the BLUE proxy card FOR ALL the Company's highly qualified and experienced director nominees. Shareholders are reminded that their vote is important, no matter how many or how few shares they own. Voting the WHITE proxy card, even in protest, will revoke any previous proxy submitted using the BLUE proxy card. Only the latest-dated proxy counts."

06:49 EDT ITT sells InTelCo Management to to Delticus HoldCo - ITT announced that it has divested InTelCo Management, a wholly owned subsidiary that holds long-term liabilities including asbestos liabilities and related insurance assets, to Delticus HoldCo, L.P., a corporate liability consolidation vehicle and portfolio company of Warburg Pincus. The estimated impact of the divesture will be a one-time after-tax loss of approximately $27M to be recorded in the second quarter and excluded from adjusted earnings per share. Delticus has acquired 100% of the equity of InTelCo, which indemnifies ITT for all legacy asbestos liabilities. At closing, ITT contributed approximately $398M in cash to InTelCo. As a result of the transaction, ITT removed all asbestos obligations, related insurance assets and associated deferred tax assets from the company's consolidated balance sheet. Delticus will assume the operational management of InTelCo, including the administration of all the asbestos claims and collection of existing insurance policy reimbursements.

06:38 EDT Immunic receives FDA clearance for ENSURE program IND - Immunic, announced FDA clearance of its investigational new drug, or IND, application for the phase 3 ENSURE program of lead asset IMU-838, the company's selective oral DHODH inhibitor, in patients with relapsing-remitting multiple sclerosis, or RRMS. In addition, the FDA also cleared the company's separate IND application for the supportive phase 2 CALLIPER trial of IMU-838 in patients with progressive multiple sclerosis, or PMS.

06:35 EDT Bowlero to list on NYSE through merger with Isos Acquisition

06:32 EDT Chart Industries acquires L.A. Turbine for $80M in cash - Chart Industries announced the acquisition of L.A. Turbine for $80M in cash. L.A. Turbine is a global leader in turboexpander design, engineering, manufacturing, assembly and testing process for new and aftermarket equipment, with significant in-house engineering expertise. Chart said, "LAT is expected to be immediately accretive to Chart, with 2021 positive impact to full year guidance to be shared on Chart's second quarter 2021 earnings call which is scheduled for July 22, 2021. Looking ahead to 2022, when we will have ramped up our combined benefits, L.A. Turbine is expected to contribute between $40 and $50 million of revenue and $0.20 to $0.30 of non-diluted earnings per share on approximately 35.5 million weighted shares outstanding (assuming tax rate of 18%). Additionally, our total addressable market for our specialty products is expanded by $350 million resulting from this acquisition - the result of the expanded TAM for hydrogen liquefaction, helium liquefaction and carbon capture with energy storage. This addition brings our total near-term specialty products addressable market size to $6.6 billion."

06:31 EDT Oyster Point Pharma's OC-01 nasal spray shows COVID-19 protection - Oyster Point Pharma announced preclinical data in non-human primates and in vitro models evaluating OC-01 - varenicline - nasal spray against SARS-CoV-2 and the alpha and beta variants, the viruses that cause COVID-19 disease. Administration of OC-01 nasal spray protected rhesus macaques against SARS-CoV-2 nasal infection. The results were published on the preprint server bioRxiv. Administration of OC-01 resulted in inhibition of cellular entry and replication of SARS-CoV-2. The absence of sgRNA indicates that the SARS-CoV-2 virus had not significantly infected nasal mucosa cells to start the transcription process of building new infectious virions. The absence of sgRNA following this very high viral inoculum also suggests the possibility of transmission may be substantially reduced after treatment with OC-01. In a separate study, researchers evaluated the in vitro antiviral activity of varenicline against SARS-CoV-2 and SARS-CoV-2 alpha and beta variants. The "promising" in vitro and in vivo data suggest a clinical path forward for OC-01. Further studies investigating the mechanism of action and its effect on other variants of concern, such as the gamma and delta variants are ongoing. Additionally, OC-02 - simpinicline - was evaluated for in vitro antiviral activity against the SARS-CoV-2 alpha variant. Simpinicline demonstrated potent antiviral activity against the SARS-CoV-2 variants in cell culture with an IC50 of 0.04 microM. Further studies investigating the antiviral effect on other variants of concern are ongoing. OC-01 and OC-02 nasal sprays have not been proven safe or effective to prevent SARS-CoV-2 infection or treat COVID-19 in humans, nor been approved for any use by the FDA. The PDUFA target action date for OC-01 nasal spray is October 17, with a planned U.S. launch in Q4, if approved by the FDA.

06:16 EDT Nissan unveils EV36Zero, GBP 1B electric vehicle hub - Nissan has unveiled Nissan EV36Zero, a GBP 1B flagship Electric Vehicle hub. Nissan said in a statement: "Centered around the record-breaking plant in Sunderland, UK, Nissan EV36Zero will supercharge the company's drive to carbon neutrality and establish a new 360-degree solution for zero-emission motoring. The transformational project has been launched with an initial GBP 1bn investment by Nissan and its partners Envision AESC, a global player in world-leading battery technology, and Sunderland City Council. Comprised of three interconnected initiatives, Nissan EV36Zero brings together electric vehicles, renewable energy and battery production, setting a blueprint for the future of the automotive industry." As part of the GBP 1 billion announcement, Nissan will invest up to GBP 423 million to produce a new-generation all-electric vehicle in the UK. Production in Sunderland will create 909 new jobs at the plant, and more than 4,500 in the UK supply chain, while safeguarding a further 75 R&D jobs, Nissan added.

06:07 EDT MKS Instruments to acquire Atotech for $16.20 in cash plus stock - MKS Instruments (MKSI) and Atotech (ATC) announced that they have entered into a definitive agreement pursuant to which MKS will acquire Atotech for $16.20 in cash and 0.0552 of a share of MKS common stock for each Atotech common share. The equity value of the transaction is $5.1B and the enterprise value of the transaction is approximately $6.5B. The transaction will result in pro forma annual revenue of $3.8B and is expected to be accretive to MKS' Non-GAAP net earnings per share within the first year and additive to MKS' free cash flow. MKS expects to realize $50M in annualized cost synergies within 18 to 36 months. MKS intends to fund the cash portion of the transaction with a combination of available cash on hand and committed debt financing. The combined company is expected to have pro forma net cash and investments of approximately $800M and total debt outstanding of $5.3B at closing, with an estimated gross leverage ratio of under 4.0 times and net leverage ratio of under 3.5 times.2 MKS has also obtained a commitment to replace its current $100M asset-based revolving credit facility with a $500M revolving credit facility. The transaction, expected to be implemented by way of a scheme of arrangement of Atotech under the laws of Jersey, has been unanimously approved by the MKS and Atotech boards of directors and is subject to Atotech shareholder approval, approval of the Royal Court of Jersey, regulatory approvals, and other customary closing conditions, and is expected to close by the fourth quarter of 2021. Carlyle (CG) and its affiliates, owner of 79% of outstanding Atotech common shares, have signed an irrevocable agreement to vote in favor of the transaction.80% of shares owned by Carlyle will be subject to a 30-day lock-up period post-closing and 60% of shares owned by Carlyle will be subject to a 60-day lock-up period post-closing.

06:03 EDT Avient acquires Magna Colours for $48M - Avient announced it has acquired Magna Colours for $48M. The MagnaColours materials will join Avient's existing specialty inks portfolio, alongside brands such as Wilflex and Rutland. Founded in 1978 and based in Barnsley, United Kingdom, Magna has pioneered the development of next-generation water-based ink technology that provides solutions for brands and screen printers.

06:01 EDT MKS Instruments to acquire Atotech for $16.20 in cash

05:31 EDT Addex Therapeutics announces mGlu2 research published in Nature - Addex Therapeutics (ADXN) announced research revealing structures of the metabotropic glutamate receptor 2, or mGlu2, in complex with one of Addex's mGlu2 positive allosteric modulators, or PAMs. The study, published in Nature, was headed by Professor Georgios Skiniotis in collaboration with the University of Copenhagen and Addex. The Nature publication explains how the mGlu2 receptor undergoes conformational transitions from an inactive to an active state. These novel structures, along with the allosteric binding site revealed through site directed mutagenesis of residues within the transmembrane domain, provides a better understanding on the function of mGlu2 receptors. This information can be used for computer aided drug discovery and will help accelerate optimization of allosteric compounds. Addex has developed capabilities that have allowed the industrialization of allosteric modulator discovery, including extensive expertise in targeting the mGlu2 receptor. ADX71149 is a novel orally active mGlu2 PAM. Addex's partner, Janssen Pharmaceuticals, part of the Janssen Pharmaceutical companies of Johnson & Johnson (JNJ), has recently started a placebo-controlled Phase 2a proof of concept clinical trial of ADX71149 in epilepsy patients. In-house, Addex is advancing mGlu2 negative allosteric modulators, or NAM, as a novel orally available treatment for mild neurocognitive disorders associated with Alzheimer's disease, Parkinson's disease and depressive disorders. Optimization of multiple chemical series' of highly selective mGlu2 NAMs is ongoing, with several compounds at the late stage of lead optimization.

05:26 EDT STMicroelectronics launches up to $1.04B share buy-back program - STMicroelectronics announced the launch of a share buy-back program of up to $1.04B to be executed within a three-year period following the publication of this press release. The share buy-back program will be carried out in accordance with the authorization of the Supervisory Board and the provisions of the Market Abuse Regulation and Commission Delegated Regulation. The company intends to carry out the buy-back program, and hold the shares bought back as treasury stock, for the purpose of meeting the company's obligations in relation to its employee stock award plans and to support the potential settlement of its outstanding convertible bond. As of June 28, the company holds approximately 8M treasury shares, representing approximately 0.9% of its issued share capital.

05:19 EDT Nio reports June deliveries up 116.1%, Q2 deliveries up 111.9% - NIO announced its June and Q2 delivery results. NIO delivered 8,083 vehicles in June, a new monthly record representing 116.1% year-over-year growth. The deliveries consisted of 1,498 ES8s, the company's six-seater or seven-seater smart electric SUV, 3,755 ES6s, the company's five-seater smart electric SUV, and 2,830 EC6s, the company's five-seater smart electric coupe SUV. NIO delivered 21,896 vehicles in the three months ended June, a new quarterly record representing a strong increase of 111.9% year-over-year. As of June 30, cumulative deliveries of the ES8, ES6 and EC6 reached 117,597 vehicles.

05:12 EDT Accenture acquires Trivadis, terms undisclosed - Accenture has entered into an agreement to acquire Trivadis, an IT services provider specializing in platforms and solutions that enable highly automated provisioning and use of data. Trivadis's team of more than 710 professionals located across Switzerland, Germany, Austria, Denmark, and Romania will join Accenture's Data & AI team within the Accenture Cloud First group. Financial terms of the acquisition were not disclosed.

05:05 EDT XPeng reports June deliveries up 617%, Q2 deliveries up 439% - XPeng announced its vehicle delivery results for June and Q2. XPeng recorded its highest-ever monthly deliveries in June of 6,565 Smart EVs, representing a 617% increase year-over-year, and a 15% increase over last month. The company also achieved a quarterly record of 17,398 deliveries in Q2, marking a 439% increase year-over-year. June deliveries consisted of 4,730 P7s, the company's sports smart sedan, and 1,835 G3s, its smart compact SUV. As of June 30, year-to-date total deliveries reached 30,738 units, representing a 459% increase year-over-year. P7 deliveries continued record-breaking growth in June. Since mid-2020, 34,588 P7s have been delivered. The company plans to launch the G3i SUV, the new mid-phase facelift version of G3, in July, with deliveries planned for September this year. XPeng also plans to launch its third production model, the P5 family-friendly smart sedan, in Q3 with deliveries expected in Q4. Upon delivery, the P5 will be the world's first mass-produced Smart EV equipped with auto-grade LiDAR technology.